- Accession Number
Semisynthetic conjugates of various toxic molecules, including RADIOACTIVE ISOTOPES and bacterial or plant toxins, with specific immune substances such as IMMUNOGLOBULINS; MONOCLONAL ANTIBODIES; and ANTIGENS. The antitumor or antiviral immune substance carries the toxin to the tumor or infected cell where the toxin exerts its poisonous effect.
Drug Drug Description Gemtuzumab ozogamicin A monoclonal anti-CD33 antibody used to treat CD33-positive acute myeloid leukemia. Coltuximab ravtansine Investigated for use/treatment in lymphoma (non-hodgkin's). Moxetumomab pasudotox A CD22-specific antibody conjugated to a truncated exotoxin used to treat relapsed or refractory hairy cell leukemia in patients who have already been treated with a purine nucleoside analog and one other treatment. Naratuximab emtansine Naratuximab emtansine is under investigation in clinical trial NCT01534715 (IMGN529 in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma and Chronic Lymphocytic Leukemia). Lorvotuzumab mertansine Lorvotuzumab mertansine has been used in trials studying the treatment of SCLC, Leukemia, Ovarian Cancer, Multiple Myeloma, and Merkel Cell Carcinoma, among others. Trastuzumab emtansine An antineoplastic agent and antibody-drug conjugate used to treat HER2-overexpressing breast cancer. Inotuzumab ozogamicin An antibody-drug conjugate used to treat B-cell precursor acute lymphoblastic leukemia (ALL). Brentuximab vedotin A CD30-directed antibody-drug conjugate used to treat various types of lymphoma. Cantuzumab mertansine Not Annotated XMMME-001-RTA Not Annotated XomaZyme-791 Not Annotated
- Drugs & Drug Targets